Early High-Dose Erythropoietin and Cognitive Functions of School-Aged Children Born Very Preterm.

Autor:	Wehrle FM; Child Development Center, University Children's Hospital Zurich, Zurich, Switzerland.; Department of Neonatology and Intensive Care, University Children's Hospital Zurich, Zurich, Switzerland.; Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland., Held U; Department of Biostatistics at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland., Disselhoff V; Department of Neonatology and Intensive Care, University Children's Hospital Zurich, Zurich, Switzerland., Schnider B; Department of Neonatology and Intensive Care, University Children's Hospital Zurich, Zurich, Switzerland., Stöckli A; Department of Neonatology and Intensive Care, University Children's Hospital Zurich, Zurich, Switzerland., Toma M; Department of Neonatology and Intensive Care, University Children's Hospital Zurich, Zurich, Switzerland., Bucher HU; Newborn Research, Department of Neonatology, University Hospital Zurich, Zurich, Switzerland., Fauchère JC; Newborn Research, Department of Neonatology, University Hospital Zurich, Zurich, Switzerland., Natalucci G; Newborn Research, Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.; Family Larsson-Rosenquist Center for Neurodevelopment, Growth and Nutrition of the Newborn, Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Hüppi P; Division of Development and Growth, Department of Woman, Child and Adolescent, University Hospitals of Geneva, Geneva, Switzerland., Borradori-Tolsa C; Division of Development and Growth, Department of Woman, Child and Adolescent, University Hospitals of Geneva, Geneva, Switzerland., Liverani MC; Division of Development and Growth, Department of Woman, Child and Adolescent, University Hospitals of Geneva, Geneva, Switzerland., O'Gorman RL; University of Zurich, Zurich, Switzerland.; Center for MR Research, University Children's Hospital Zurich, Zurich, Switzerland., Latal B; Child Development Center, University Children's Hospital Zurich, Zurich, Switzerland.; Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Hagmann CF; Department of Neonatology and Intensive Care, University Children's Hospital Zurich, Zurich, Switzerland.; Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland.
Jazyk:	angličtina
Zdroj:	JAMA network open [JAMA Netw Open] 2024 Sep 03; Vol. 7 (9), pp. e2430043. Date of Electronic Publication: 2024 Sep 03.
DOI:	10.1001/jamanetworkopen.2024.30043
Abstrakt:	Importance: Children born very preterm are at risk for long-term neurodevelopmental sequelae. Prophylactic high-dose recombinant human erythropoietin (rhEpo) shortly after birth has not been shown to improve cognitive, motor, and behavioral development at 2 and 5 years. Objective: To investigate whether early high-dose rhEpo is associated with better executive functions and processing speed-late-maturing cognitive functions-in school-aged children born very preterm. Design, Setting, and Participants: This single-center cohort study was a prospective, observational follow-up study of a multicenter neonatal clinical trial; 365 children born very preterm (mean gestational age, 29.3 weeks [range, 26.0-31.9 weeks]) who had been enrolled in the Swiss EPO Neuroprotection Trial at birth between 2005 and 2012, and who were included in the primary outcome analyses at 2 years, were eligible to be recruited for the EpoKids study between 2017 and 2021 when they were at school age. Term-born children were additionally recruited and included in a control group. Data were analyzed between May and September 2022. Exposure: Administration of rhEpo (3000 IU/kg) or placebo (saline, 0.9%) intravenously 3 times within the first 2 days of life as part of the Swiss EPO Neuroprotection Trial. Main Outcome and Measures: A comprehensive neuropsychological test battery assessed executive functions and processing speed, and parents reported on their child's executive functions in everyday life to test the hypothesis that early high-dose rhEpo administration is associated with better cognitive outcomes at school age. Results: In the EpoKids study, 214 children born very preterm (58.6% of 365 children in eligible cohort) were assessed at a mean age of 10.4 years (range, 6.9-13.4 years); 117 (54.7%) were boys. There was no evidence that the 117 children who had received rhEpo differed from the 97 children who had received placebo in any of the 15 executive function and processing speed tests, nor in parent-rated executive functions (estimates ranged from -0.138 to 0.084, all 95% CIs included 0). Irrespective of rhEpo or placebo allocation, children born very preterm scored lower on 11 of 15 executive function and processing speed tests than term-born peers (estimates ranged from 0.112 to 0.255, 95% CIs did not include 0). Conclusion and Relevance: This study found no evidence for a positive association between prophylactic early high-dose rhEpo administration and long-term neurodevelopmental outcomes after very preterm birth. These results suggest that a comprehensive approach, including pharmacological and nonpharmacological prevention and intervention strategies, is needed to support these children's neurodevelopmental outcome.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu